BioAtla And Context Therapeutics Set To Develop And Commercialize Innovative T Cell Engaging Antibody

A global, clinical-stage biotechnology company BioAtla, Inc., is a platform primarily focused on developing (CAB) Conditionally Active Biologic, an antibody therapeutics for treating solid tumours. On the other hand, Context Therapeutics Inc. is a biopharmaceutical company intent on advancing (TCE) T-cells engaging bispecific antibodies for solid tumours. 

Today, both the companies announced their enrollment in an agreement under which Context obtained a worldwide exclusive licence from BioAtla to manufacture, develop, and commercialise BA3362, BioAtla’s Nectin-4 x CD3 TCE. The Context Therapeutics will accept and sponsor all commercialisation and development activities. Context Therapeutics predicts the IND (Investigational New Drug) filling for BA3362 in mid-2026.

In up-front and approaching milestones, BioAtla will receive $15.0 million, with potential regulatory, clinical, and commercial milestones estimated to scale up to $118.5 million, added royalties on net sales. 

BioAtla was advised by Tungsten Advisors on financial matters and by Orrick, Herrington & Sutcliffe LLP on legal issues. Context received financial guidance from Piper Sandler and legal counsel from Goodwin Procter LLP.

With the successful out-licensing of BA3362 to Context, we will continue to focus on execution of our lead clinical CAB programs, while ensuring the potential advancement of BA3362 under the leadership of a seasoned team. We believe this transaction marks the first of multiple collaborations, including a targeted collaboration for one of our Phase 2 assets over the coming months, thereby increasing shareholder value through non-dilutive means,” stated Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla. 

Martin Lehr, CEO of Context, said “This transaction is consistent with our focus on building a pipeline of TCE assets through strategic in-licensing or acquisition. Nectin-4 is a priority target for Context given the target’s high prevalence in solid tumours and the unmet need to address potential resistance to Nectin-4 antibody-drug conjugates. 

He further added, “We identified BioAtla's Nectin-4 TCE antibody as a potentially best-in-class asset. BA3362 is built from BioAtla’s compelling CAB platform technology that uses pH-dependency to drive selective Nectin-4 binding and T cell activation within the tumour microenvironment.”